Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, Elahere and Ovarian Cancer
AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab ...
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed in February.
European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer. The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive,
20h
What You Should Know About Ovarian Cancer Vaccines
Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...
thehealthy
2d
Patrick Dempsey Opens Up About His Passion for Cancer Awareness
It’s hard to believe it was almost 20 years ago when in 2005, Patrick Dempsey originated the role of Dr. Derek Shepherd in a ...
3h
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...
mayo
2d
Project 1: Next-Generation TOP1 Inhibition To Treat Ovarian Cancer
TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...
Medpage Today on MSN
4d
Adding HIPEC Boosts Survival in Recurrent Ovarian Cancer
The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
Radio Iowa
5d
UI is crafting a new drug to treat ovarian cancer
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
mayo
2d
Project 4: Th17 T Cell-Inducing Vaccines for the Prevention of Ovarian Cancer Recurrence
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
6d
Kathy Bates Reveals Why She Decided Against Reconstruction After Breast Cancer: 'I Enjoy Not Having Breasts'
Kathy Bates has revealed why she decided against reconstruction surgery after her breast cancer diagnosis and mastectomy in ...
The American Journal of Managed Care
5d
Ovarian Cancer Survival Varies Widely Among Asian American Subgroups
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
European Commission
Elahere
AbbVie Inc.
Feedback